CDMO– tag –
-
ProBio’s AAV Manufacturing Excellence Accelerates UC Irvine and GlyTR Therapeutics’ Pan-Cancer CAR-T Program, Achieving 80% CAR Gene Insertion Efficiency
University of California, Irvine USA Overview ProBio's advanced AAV manufacturing technology is critically powering pre-IND research for the first-in-class pan-cancer CAR-T program developed by UC Irvine and GlyTR Therapeutics. ProBio's ... -
Porton Advanced Fortifies End-to-End ATMP CDMO Services with Over 250 Global Clients
Porton Advanced China Overview Porton Advanced is strengthening its end-to-end CDMO solutions for Advanced Therapy Medicinal Products (ATMPs), serving over 250 global customers. The company offers cell engineering CMC services for autolo... -
MaxCyte & VectorBuilder Partner on Virus-Free Gene Delivery Platform for Ex Vivo Cell Therapies, Boosting CAR T-Cell Manufacturability
BioProcess International USA Overview CDMO VectorBuilder and MaxCyte have partnered to develop a virus-free gene delivery platform for ex vivo cell therapies, including CAR T cells. This collaboration integrates VectorBuilder's 'MiniVec'... -
Lonza Expands Collaboration with Major US Biopharma, Secures Commercial Production for Two Biologics Programs
Lonza Switzerland Overview Lonza has expanded its strategic collaboration with a leading US biopharmaceutical company, securing commercial production for two biologics programs with options for two more. This expansion reflects robust de... -
Market Report: US Autologous CAR-T Cell Therapy Process Optimization Market Driven by Efficiency & Cost Reduction Needs
Intel Market Research USA Overview This article summarizes the "United States Autologous CART Cell Therapy Process Optimization Market Outlook 2026-2034" report. The US autologous CAR-T cell therapy process optimization market is driven ... -
Histocell Accelerates Advanced Cell Therapy Production with New 800m² GMP Facility, Targeting 1,200 Annual Batches
REPROCELL Spain Overview Histocell has inaugurated an 800m² Advanced Therapies GMP facility, dramatically increasing its cell manufacturing capacity to an estimated 1,200 batches annually for both autologous and allogeneic treatments. Th... -
Biologics Outsourcing Redefined: Modality Expertise & End-to-End Integration Key for Partnerships
Bioprocess Online USA Overview Biologics manufacturing outsourcing is evolving into strategic partnerships focused on modality expertise, regulatory excellence, and end-to-end integration, moving beyond mere cost savings. To support incr... -
CDMO Signal Ranks Top FDA & GMP-Compliant Lentiviral Vector Manufacturing CDMOs
CDMO Signal Global Overview CDMO Signal has released a ranking of top Lentiviral Vector (LVV) CDMOs, crucial for ex vivo gene therapy, based on FDA inspection history, GMP certification, clinical program activity, and capacity. LVVs are ... -
Novo Nordisk Partners with India’s Shantha Biologics for Global Cartridge Fill-Finish Services
The SouthFirst India Overview Novo Nordisk has signed an outsourcing agreement with Hyderabad-based Shantha Biologics for cartridge fill-finish manufacturing services for its global supply chain. This strategic collaboration signifies Sh... -
PackGene Biotech Accelerates Next-Gen CAR-T Development with Lentiviral and mRNA Technologies
PackGene Biotech China Overview PackGene Biotech is advancing next-generation CAR-T cell development by offering both lentiviral vector (LVV) and mRNA technologies for manufacturing. LVVs are a core technology enabling stable, long-term ...
